Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.
Heart failure
Heart failure with preserved ejection fraction
Phenotype
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
08
05
2023
received:
07
02
2023
accepted:
09
05
2023
medline:
9
8
2023
pubmed:
18
7
2023
entrez:
18
7
2023
Statut:
ppublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
936-955Informations de copyright
© 2023 European Society of Cardiology.
Références
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease study 2017. Lancet. 2018;392:1789-1858. https://doi.org/10.1016/S0140-6736(18)32279-7
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342-1356. https://doi.org/10.1002/ejhf.1858
McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:602-611. https://doi.org/10.1016/j.jacc.2018.11.033
Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: A review. JAMA. 2020;324:488-504. https://doi.org/10.1001/jama.2020.10262
Senni M, Greene SJ, Butler J, Fonarow GC, Gheorghiade M. Drug development for heart failure with preserved ejection fraction: What pieces are missing from the puzzle? Can J Cardiol. 2017;33:768-776. https://doi.org/10.1016/j.cjca.2017.03.013
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. https://doi.org/10.1056/NEJMoa2107038
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23:1217-1225. https://doi.org/10.1002/ejhf.2249
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2020;384:117-128. https://doi.org/10.1056/NEJMoa2030183
Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, et al.; EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-686. https://doi.org/10.1161/CIRCULATIONAHA.122.059785
Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail. 2022;10:184-197. https://doi.org/10.1016/j.jchf.2021.11.006
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-767. https://doi.org/10.1016/S0140-6736(22)01429-5
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. https://doi.org/10.1056/NEJMoa1313731
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255
de Denus S, O'Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT - new insights into regional variation. N Engl J Med. 2017;376:1690-1692. https://doi.org/10.1056/NEJMc1612601
ClinicalTrials.gov. Spironolactone in the Treatment of Heart Failure (SPIRIT-HF). https://clinicaltrials.gov/ct2/show/NCT04727073. Accessed 15 May 2023.
ClinicalTrials.gov. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT). https://clinicaltrials.gov/ct2/show/NCT02901184. Accessed 15 May 2023.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Pandey A, Parashar A, Kumbhani DJ, Agarwal S, Garg J, Kitzman D, et al. Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33-40. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001615
Boulmpou A, Theodorakopoulou MP, Boutou AK, Alexandrou ME, Papadopoulos CE, Bakaloudi DR, et al. Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: A systematic review and meta-analysis. Hellenic J Cardiol. 2022;64:58-66. https://doi.org/10.1016/j.hjc.2021.10.003
Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017;69:1129-1142. https://doi.org/10.1016/j.jacc.2016.11.081
Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6-19. https://doi.org/10.1161/CIRCULATIONAHA.116.026807
Guo Y, Xiao C, Zhao K, He Z, Liu S, Wu X, et al. Physical exercise modalities for the management of heart failure with preserved ejection fraction: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022;79:698-710. https://doi.org/10.1097/FJC.0000000000001254
Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, et al. OptimEx-Clin Study Group. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2021;325:542-551. https://doi.org/10.1001/jama.2020.26812
Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019;74:601-612. https://doi.org/10.1016/j.jacc.2019.05.052
Lin Y, Fu S, Yao Y, Li Y, Zhao Y, Luo L. Heart failure with preserved ejection fraction based on aging and comorbidities. J Transl Med. 2021;19:291. https://doi.org/10.1186/s12967-021-02935-x
Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, et al.; EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age. J Am Coll Cardiol. 2022;80(1):1-18. https://doi.org/10.1016/j.jacc.2022.04.040
De Bellis A, De Angelis G, Fabris E, Cannatà A, Merlo M, Sinagra G. Gender-related differences in heart failure: Beyond the “one-size-fits-all” paradigm. Heart Fail Rev. 2020;25:245-255. https://doi.org/10.1007/s10741-019-09824-y
Beale AL, Meyer P, Marwick TH, Lam CS, Kaye DM. Sex differences in cardiovascular pathophysiology: Why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 2018;138:198-205. https://doi.org/10.1161/CIRCULATIONAHA.118.034271
Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Düngen HD, et al. Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol. 2011;100:755-764. https://doi.org/10.1007/s00392-011-0305-4
Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GM, et al. Sex-based differences in heart failure across the ejection fraction spectrum: Phenotyping, and prognostic and therapeutic implication. JACC Heart Fail. 2019;7:505-515. https://doi.org/10.1016/j.jchf.2019.03.011
Butler J, Filippatos G, Siddiqi TJ, Ferreira JP, Brueckmann M, Bocchi E, et al. Effects of empagliflozin in women and men with heart failure and preserved ejection fraction. Circulation. 2022;146:1046-1055. https://doi.org/10.1161/CIRCULATIONAHA.122.059755
Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, et al. Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: Insights from DAPA-HF and DELIVER. Circulation. 2023;147:624-634. https://doi.org/10.1161/CIRCULATIONAHA.122.062832
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF. Circulation. 2020;141:338-351. https://doi.org/10.1161/CIRCULATIONAHA.119.044491
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853-872. https://doi.org/10.1002/ejhf.1170
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet. 2003;362:759-766. https://doi.org/10.1016/s0140-6736(03)14282-1
Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135:724-735. https://doi.org/10.1161/CIRCULATIONAHA.116.024593
Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-1620. https://doi.org/10.1056/NEJMoa1908655
Kristensen SL, Jhund PS, Lee MM, Køber L, Solomon SD, Granger CB, et al.; CHARM Investigators and Committees. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther. 2017;31:545-549. https://doi.org/10.1007/s10557-017-6754-x
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574-1585. https://doi.org/10.1002/ejhf.813
Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9-20. https://doi.org/10.1016/j.ahj.2016.07.025
Tromp J, Claggett BL, Liu J, Jackson AM, Jhund PS, Køber L, et al.; PARAGON-HF Investigators. Global differences in heart failure with preserved ejection fraction: The PARAGON-HF trial. Circ Heart Fail. 2021;14:e007901. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007901
Bank IEM, Gijsberts CM, Teng TK, Benson L, Sim D, Yeo PSD, et al. Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure. JACC Heart Fail. 2017;5:14-24. https://doi.org/10.1016/j.jchf.2016.09.015
Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718-1727. https://doi.org/10.1093/eurheartj/ehv134
Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metabol. 2008;93:1143-1152. https://doi.org/10.1210/jc.2007-1817
Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4:90-102. https://doi.org/10.4330/wjc.v4.i4.90
Amaral N, Okonko DO. Metabolic abnormalities of the heart in type II diabetes. Diab Vasc Dis Res. 2015;12:239-248. https://doi.org/10.1177/1479164115580936
Bayeva M, Sawicki KT, Ardehali H. Taking diabetes to heart - deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc. 2013;2:e000433. https://doi.org/10.1161/JAHA.113.000433
McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175. https://doi.org/10.1161/CIRCULATIONAHA.106.645614
Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006;98:596-605. https://doi.org/10.1161/01.RES.0000207406.94146.c2
Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006;47:598-604. https://doi.org/10.1016/j.jacc.2005.09.030
Krüger M, Babicz K, von Frieling-Salewsky M, Linke WA. Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol. 2010;48:910-916. https://doi.org/10.1016/j.yjmcc.2010.02.012
Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocrine Metabolic Disord. 2010;11:61-74. https://doi.org/10.1007/s11154-010-9134-4
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772. https://doi.org/10.1161/CIRCULATIONAHA.116.021887
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. https://doi.org/10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. https://doi.org/10.1056/NEJMoa1611925
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357. https://doi.org/10.1056/NEJMoa1812389
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al.; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-1435. https://doi.org/10.1056/NEJMoa2004967
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. https://doi.org/10.1056/NEJMoa1811744
Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.; DAPA-CKD Trial Committees and Investigators; 10.1056/NEJMoa2024816. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al.; SCORED Investigators; 10.1056/NEJMoa2030186. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129-139.
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol. 2021;6:148-158. https://doi.org/10.1001/jamacardio.2020.4511
Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, et al. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. Eur J Heart Fail. 2020;22:1984-1986. https://doi.org/10.1002/ejhf.2026
Selvaraj S, Martinez EE, Aguilar FG, Kim KY, Peng J, Sha J, et al. Association of central adiposity with adverse cardiac mechanics: Findings from the Hypertension Genetic Epidemiology Network study. Circ Cardiovasc Imaging. 2016;9:e004396. https://doi.org/10.1161/CIRCIMAGING.115.004396
Sarma S, MacNamara J, Livingston S, Samels M, Haykowsky MJ, Berry J, et al. Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction. Physiol Rep. 2020;8:e14634. https://doi.org/10.14814/phy2.14634
Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou-Ezzedine OF, Fudim M, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: A RELAX trial ancillary study. Mayo Clin Proc. 2019;94:1199-1209. https://doi.org/10.1016/j.mayocp.2018.11.037
Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U. Cardiovascular effects of current and future anti-obesity drugs. Curr Vasc Pharmacol. 2014;12:493-504. https://doi.org/10.2174/1570161112666140423223529
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. https://doi.org/10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. https://doi.org/10.1056/NEJMoa2206038
Müller M, de Jong M, Jaarsma T, Koops A, Voors AA, Nieuwenhuis JA, et al. Central sleep apnoea syndrome in chronic heart failure: An underestimated and treatable comorbidity. Neth Heart J. 2010;18:260-263. https://doi.org/10.1007/BF03091773
Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095-1105. https://doi.org/10.1056/NEJMoa1506459
National Institutes of Health. Effect of adaptive servo ventilation (ASV) on survival and hospital admissions in heart failure (ADVENT-HF). 2015.
Yoshihisa A, Suzuki S, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing. Eur J Heart Fail. 2013;15:543-550. https://doi.org/10.1093/eurjhf/hfs197
McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10:149-156. https://doi.org/10.1016/j.ejheart.2007.12.010
Lam CS, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39:1770-1780. https://doi.org/10.1093/eurheartj/ehy005
Kasiakogias A, Rosei EA, Camafort M, Ehret G, Faconti L, Ferreira JP, et al. Hypertension and heart failure with preserved ejection fraction: Position paper by the European Society of Hypertension. J Hypertens. 2021;39:1522-1545. https://doi.org/10.1097/HJH.0000000000002910
Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691-728. https://doi.org/10.1089/ars.2006.8.691
Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624-1634. https://doi.org/10.1002/ejhf.945
Teng THK, Tay WT, Dahlstrom U, Benson L, Lam CS, Lund LH. Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;254:203-209. https://doi.org/10.1016/j.ijcard.2017.09.187
Gu J, Fan YQ, Zhang HL, Zhang JF, Wang CQ. Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. J Clin Hyperten (Greenwich). 2018;20:560-567. https://doi.org/10.1111/jch.13210
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. https://doi.org/10.1056/NEJMoa0801369
Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: A meta-analysis. Am J Hypertens. 2015;28:1453-1463. https://doi.org/10.1093/ajh/hpv050
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957-967. https://doi.org/10.1016/S0140-6736(15)01225-8
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-2295. https://doi.org/10.1097/HJH.0000000000000378
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. https://doi.org/10.1093/eurheartj/ehl250
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al.; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467. https://doi.org/10.1056/NEJMoa0805450
Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352-361. https://doi.org/10.1161/CIRCULATIONAHA.119.044586
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776-803. https://doi.org/10.1016/j.jacc.2017.04.025
Selvaraj S, Claggett BL, Böhm M, Anker SD, Vaduganathan M, Zannad F, et al. Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. J Am Coll Cardiol. 2020;75:1644-1656. https://doi.org/10.1016/j.jacc.2020.02.009
Huang R, Lin Y, Liu M, Xiong Z, Zhang S, Zhong X, et al. Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2022;11:e022765. https://doi.org/10.1161/JAHA.121.022765
Faselis C, Lam PH, Zile MR, Bhyan P, Tsimploulis A, Arundel C, et al. Systolic blood pressure and outcomes in older patients with HFpEF and hypertension. Am J Med. 2021;134:e252-e263. https://doi.org/10.1016/j.amjmed.2020.08.030
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al.; Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55:241-248. https://doi.org/10.1161/HYPERTENSIONAHA.109.138529
Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, et al. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013;34:676-683. https://doi.org/10.1093/eurheartj/ehs299
Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure. JACC Heart Fail. 2017;5:810-819. https://doi.org/10.1016/j.jchf.2017.08.015
Böhm M, Ewen S. Blood pressure risk associations in heart failure: True effects or inverse causality? JACC Heart Fail. 2017;5:820-822. https://doi.org/10.1016/j.jchf.2017.09.010
Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: Contemporary update. JACC Heart Fail. 2017;5:543-551. https://doi.org/10.1016/j.jchf.2017.04.012
Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol. 2009;53:1119-1126. https://doi.org/10.1016/j.jacc.2008.11.051
Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74:2858-2873. https://doi.org/10.1016/j.jacc.2019.09.063
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119. https://doi.org/10.1093/eurheartj/ehv317
Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: Pulmonary hypertension and heart failure. JACC Heart Fail. 2013;1:290-299. https://doi.org/10.1016/j.jchf.2013.05.001
Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre-and postcapillary pulmonary hypertension: A randomized open-label pilot study. BMC Cardiovasc Disord. 2020;20:408. https://doi.org/10.1186/s12872-020-01671-2
Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174. https://doi.org/10.1161/CIRCULATIONAHA.110.983866
Gaziano L, Cho K, Djousse L, Schubert P, Galloway A, Ho YL, et al. Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. ESC Heart Fail. 2021;8:4893-4903. https://doi.org/10.1002/ehf2.13429
Sato Y, Yoshihisa A, Oikawa M, Nagai T, Yoshikawa T, Saito Y, et al. Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction - a report from the JASPER registry. J Cardiol. 2019;73:459-465. https://doi.org/10.1016/j.jjcc.2019.01.005
Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132-139. https://doi.org/10.1016/j.ijcard.2018.04.001
Jain S, Obeid MJ, Yenigalla S, Paravathaneni M, Gadela NV, Singh G, et al. Impact of chronic obstructive pulmonary disease in heart failure with preserved ejection fraction. Am J Cardiol. 2021;149:47-56. https://doi.org/10.1016/j.amjcard.2021.03.009
Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Clinical phenogroups in heart failure with preserved ejection fraction: Detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8:172-184. https://doi.org/10.1016/j.jchf.2019.09.009
Marcun R, Stankovic I, Vidakovic R, Farkas J, Kadivec S, Putnikovic B, et al. Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Intern Emerg Med. 2016;11:519-527. https://doi.org/10.1007/s11739-015-1319-0
Reddy YN, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA. The β-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction: A randomized controlled trial. Circ Res. 2019;124:306-314. https://doi.org/10.1161/CIRCRESAHA.118.313832
Feng S, Janwanishstaporn S, Teerlink JR, Metra M, Cotter G, Davison B, et al. Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: Insights from the RELAX-AHF-2 study. Eur J Heart Fail. 2021;23:58-67. https://doi.org/10.1002/ejhf.2012
Mavrakanas TA, Khattak A, Wang W, Singh K, Charytan DM. Association of chronic kidney disease with preserved ejection fraction heart failure is independent of baseline cardiac function. Kidney Blood Press Res. 2019;44:1247-1258. https://doi.org/10.1159/000502874
Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation. Eur J Heart Fail. 2016;18:588-598. https://doi.org/10.1002/ejhf.497
Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, et al.; PARAMOUNT Investigators. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3442-3451. https://doi.org/10.1093/eurheartj/ehu254
Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18:103-112. https://doi.org/10.1002/ejhf.445
Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail. 2019;7:25-32. https://doi.org/10.1016/j.jchf.2018.10.017
Beldhuis IE, Streng KW, Ter Maaten JM, Voors AA, van der Meer P, Rossignol P, et al. Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: A meta-analysis of published study data. Circ Heart Fail. 2017;10:e003588. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003588
Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, et al. Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol. 2021;77:1211-1221. https://doi.org/10.1016/j.jacc.2020.12.057
Peikert A, Vaduganathan M, Mc Causland F, Claggett BL, Chatur S, Packer M, et al. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail. 2022;24:794-803. https://doi.org/10.1002/ejhf.2450
Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, et al.; FIGARO-DKD Investigators. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial. Circulation. 2022;145:437-447. https://doi.org/10.1161/CIRCULATIONAHA.121.057983
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-2229. https://doi.org/10.1056/NEJMoa2025845
Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D. Iron deficiency in heart failure with preserved ejection fraction: A systematic review and meta-analysis. Open Heart. 2019;6:e001012. https://doi.org/10.1136/openhrt-2019-001012
Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol. 2022;79:341-351. https://doi.org/10.1016/j.jacc.2021.11.039
Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63:2817-2827. https://doi.org/10.1016/j.jacc.2014.03.034
Shah SJ, Lam CS, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39:3439-3450. https://doi.org/10.1093/eurheartj/ehy531
Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1130-1143. https://doi.org/10.1001/jamacardio.2021.1825
Crea F, Bairey Merz CN, Beltrame JF, Kaski JC, Ogawa H, Ong P, et al.; Coronary Vasomotion Disorders International Study Group (COVADIS). The parallel tales of microvascular angina and heart failure with preserved ejection fraction: A paradigm shift. Eur Heart J. 2017;38:473-477. https://doi.org/10.1093/eurheartj/ehw461
Obokata M, Reddy YN, Melenovsky V, Kane GC, Olson TP, Jarolim P, et al. Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2018;72:29-40. https://doi.org/10.1016/j.jacc.2018.04.039
Dryer K, Gajjar M, Narang N, Lee M, Paul J, Shah AP, et al. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2018;314:H1033-H1042. https://doi.org/10.1152/ajpheart.00680.2017
Yang JH, Obokata M, Reddy YN, Redfield MM, Lerman A, Borlaug BA. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22:432-441. https://doi.org/10.1002/ejhf.1671
Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550-559. https://doi.org/10.1161/CIRCULATIONAHA.114.009625
Hwang SJ, Melenovsky V, Borlaug BA. Is revascularization an effective therapy for heart failure with preserved ejection fraction? Circulation. 2013;128:A12075.
Deo SV, Reddy YNV, Zakeri R, Karnib M, Selvaganesan P, Elgudin Y, et al. Revascularization in ischaemic heart failure with preserved ejection fraction: A nationwide cohort study. Eur J Heart Fail. 2022;24:1427-1438. https://doi.org/10.1002/ejhf.2446
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-427. https://doi.org/10.1056/NEJMoa1707855
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al.; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305-1316. https://doi.org/10.1056/NEJMoa2019422
Böhm M, Reil JC, Deedwania P, Kim JB, Borer JS. Resting heart rate: Risk indicator and emerging risk factor in cardiovascular disease. Am J Med. 2015;128:219-228. https://doi.org/10.1016/j.amjmed.2014.09.016
Nikolovska Vukadinović A, Vukadinović D, Borer J, Cowie M, Komajda M, Lainscak M, et al. Heart rate and its reduction in chronic heart failure and beyond. Eur J Heart Fail. 2017;19:1230-1241. https://doi.org/10.1002/ejhf.902
Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al.; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-894. https://doi.org/10.1016/S0140-6736(10)61259-7
Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, et al.; CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012;59:1785-1795. https://doi.org/10.1016/j.jacc.2011.12.044
Böhm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, et al.; I-Preserve Committees and Investigators. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014;16:778-787. https://doi.org/10.1002/ejhf.85
Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, et al.; prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: The EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495-1503. https://doi.org/10.1002/ejhf.876
Komajda M, Böhm M, Borer JS, Ford I, Robertson M, Manolis AJ, et al.; SHIFT Investigators. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16:810-816. https://doi.org/10.1002/ejhf.114
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet. 2010;376:875-885. https://doi.org/10.1016/S0140-6736(10)61198-1
Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, et al.; CHART-2 Investigators. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: A report from the CHART-2 study. Eur J Heart Fail. 2014;16:309-316. https://doi.org/10.1002/ejhf.22
Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I, et al.; Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. Eur J Heart Fail. 2015;17:1182-1191. https://doi.org/10.1002/ejhf.346
Wolsk E, Kaye DM, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, et al. Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2021;23:754-764. https://doi.org/10.1002/ejhf.2146
Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: Past, present, and future. Clin Res Cardiol. 2020;109:1079-1098. https://doi.org/10.1007/s00392-020-01633-w
van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, et al.; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150-2158. https://doi.org/10.1016/j.jacc.2009.02.046
Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al.; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26-35. https://doi.org/10.1093/eurheartj/ehx564
Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219-225. https://doi.org/10.1093/eurjhf/hfr161
Infeld M, Wahlberg K, Cicero J, Plante TB, Meagher S, Novelli A, et al. Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: The myPACE randomized clinical trial. JAMA Cardiol. 2023;8:213-221. https://doi.org/10.1001/jamacardio.2022.5320
Böhm M, Butler J, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Preserved Trial Committees and Investigators. Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24:1883-1891. https://doi.org/10.1002/ejhf.2677
Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845-854. https://doi.org/10.1016/j.jacc.2010.03.077
Brubaker PH, Kitzman DW. Chronotropic incompetence: Causes, consequences, and management. Circulation. 2011;123:1010-1020. https://doi.org/10.1161/CIRCULATIONAHA.110.940577
Zweerink A, van der Lingen ACJ, Handoko ML, van Rossum AC, Allaart CP. Chronotropic incompetence in chronic heart failure. Circ Heart Fail. 2018;11:e004969. https://doi.org/10.1161/CIRCHEARTFAILURE.118.004969
Domínguez E, Palau P, Núñez E, Ramón JM, López L, Melero J, et al. Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction. ESC Heart Fail. 2018;5:579-585. https://doi.org/10.1002/ehf2.12281
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. https://doi.org/10.1093/eurheartj/ehw128
Palau P, Seller J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol. 2021;78:2042-2056. https://doi.org/10.1016/j.jacc.2021.08.073
Reddy YNV, Koepp KE, Carter R, Win S, Jain CC, Olson TP, et al. Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: The RAPID-HF randomized clinical trial. JAMA. 2023;329:801-809. https://doi.org/10.1001/jama.2023.0675
Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD, et al. Atrial functional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol. 2019;73:2465-2476. https://doi.org/10.1016/j.jacc.2019.02.061
Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: Reversal with arrhythmia control. J Am Coll Cardiol. 2011;58:1474-1481. https://doi.org/10.1016/j.jacc.2011.06.032
Kajimoto K, Sato N, Takano T; Investigators of the Acute Decompensated Heart Failure Syndrome (ATTEND) Registry. Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction. Eur J Heart Fail. 2016;18:1051-1059. https://doi.org/10.1002/ejhf.562
Gertz ZM, Herrmann HC, Lim DS, Kar S, Kapadia SR, Reed GW, et al. Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT trial. Circ Cardiovasc Interv. 2021;14:e010300. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010300
Bar N, Schwartz LA, Biner S, Aviram G, Ingbir M, Nachmany I, et al. Clinical outcome of isolated tricuspid regurgitation in patients with preserved left ventricular ejection fraction and pulmonary hypertension. J Am Soc Echocardiogr. 2018;31:34-41. https://doi.org/10.1016/j.echo.2017.09.010
Muraru D, Addetia K, Guta AC, Ochoa-Jimenez RC, Genovese D, Veronesi F, et al. Right atrial volume is a major determinant of tricuspid annulus area in functional tricuspid regurgitation: A three-dimensional echocardiographic study. Eur Heart J Cardiovasc Imaging. 2021;22:660-669. https://doi.org/10.1093/ehjci/jeaa286
Harada T, Obokata M, Omote K, Iwano H, Ikoma T, Okada K, et al. Functional tricuspid regurgitation and right atrial remodeling in heart failure with preserved ejection fraction. Am J Cardiol. 2022;162:129-135. https://doi.org/10.1016/j.amjcard.2021.09.021
Ren QW, Li XL, Fang J, Chen Y, Wu MZ, Yu YJ, et al. The prevalence, predictors, and prognosis of tricuspid regurgitation in stage B and C heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7:4051-4060. https://doi.org/10.1002/ehf2.13014
Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al.; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338-1352. https://doi.org/10.1002/ejhf.1492
Kresoja KP, Lauten A, Orban M, Rommel KP, Alushi B, Besler C, et al. Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. Eur J Heart Fail. 2020;22:1817-1825. https://doi.org/10.1002/ejhf.1975
Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, et al. Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail. 2019;21:1299-1305. https://doi.org/10.1002/ejhf.1611
Konishi M. Scoring the physical frailty phenotype of patients with heart failure. J Cachexia Sarcopenia Muscle. 2022;13:5-7. https://doi.org/10.1002/jcsm.12883
Butt JH, Dewan P, Merkely B, Belohlávek J, Drożdż J, Kitakaze M, et al. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: A post hoc analysis of the DAPA-HF trial. Ann Intern Med. 2022;175:820-830. https://doi.org/10.7326/M21-4776
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, et al. Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study. Lancet. 2019;394:1254-1263. https://doi.org/10.1016/S0140-6736(19)31792-1
Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, et al. Routinely reported ejection fraction and mortality in clinical practice: Where does the nadir of risk lie? Eur Heart J. 2020;41:1249-1257. https://doi.org/10.1093/eurheartj/ehz550
Ng AC, Bax JJ. Hyperdynamic left ventricular function and the prognostic implications for heart failure with preserved ejection fraction. Eur Heart J. 2020;41:1258-1259. https://doi.org/10.1093/eurheartj/ehz706
Huang Z, Jiang Y, Zhou Y. Heart failure with supra-normal left ventricular ejection fraction - state of the art. Arq Bras Cardiol. 2021;116:1019-1022. https://doi.org/10.36660/abc.20190835
Yeboah J, Rodriguez CJ, Qureshi W, Liu S, Carr JJ, Lima JA, et al. Prognosis of low normal left ventricular ejection fraction in an asymptomatic population-based adult cohort: the Multiethnic Study of Atherosclerosis. J Card Fail. 2016;22:763-768. https://doi.org/10.1016/j.cardfail.2016.03.013
Stewart S, Playford D, Scalia GM, Currie P, Celermajer DS, Prior D, et al. Ejection fraction and mortality: A nationwide register-based cohort study of 499 153 women and men. Eur J Heart Fail. 2021;23:406-416. https://doi.org/10.1002/ejhf.2047
Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297-3317. https://doi.org/10.1093/eurheartj/ehz641
Hadzibegovic S, Lena A, Churchill TW, Ho JE, Potthoff S, Denecke C, et al. Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. Eur J Heart Fail. 2021;23:1891-1902. https://doi.org/10.1002/ejhf.2210
Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:553-576. https://doi.org/10.1002/ejhf.1461
Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-380. https://doi.org/10.1002/ejhf.2115
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al.; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-462. https://doi.org/10.1093/eurheartj/ehv464
Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43:416-426. https://doi.org/10.1093/eurheartj/ehab798
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020;13:198-210. https://doi.org/10.1016/j.jcmg.2019.07.018
Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: A systematic review with meta-analysis. Cardiol Rev. 2018;26:29-34. https://doi.org/10.1097/CRD.0000000000000161
Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, et al. Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma. Circ Heart Fail. 2018;11:e004408. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004408
Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120-127. https://doi.org/10.1016/j.ctrv.2016.12.002
Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA Adverse Event Reporting System database (FAERS). Cancers (Basel). 2020;12:826. https://doi.org/10.3390/cancers12040826
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755-1764. https://doi.org/10.1016/j.jacc.2018.02.037
Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and infiltrative cardiomyopathies: Part 2 of a 2-part series. J Am Coll Cardiol. 2018;71:1149-1166. https://doi.org/10.1016/j.jacc.2018.01.017
Del Buono MG, Buckley L, Abbate A. Primary and secondary diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol. 2018;122:1578-1587. https://doi.org/10.1016/j.amjcard.2018.07.012
González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585-2594. https://doi.org/10.1093/eurheartj/ehv338
Devesa A, Camblor Blasco A, Pello Lazaro AM, Askari E, Lapeña G, Gomez Talavera S, et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail. 2021;8:2856-2865. https://doi.org/10.1002/ehf2.13360
Klaassen SH, van Veldhuisen DJ, Nienhuis HL, van den Berg MP, Hazenberg BP, van der Meer P. Cardiac transthyretin-derived amyloidosis: An emerging target in heart failure with preserved ejection fraction? Card Fail Rev. 2020;6:e21. https://doi.org/10.15420/cfr.2019.16
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al.; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-1016. https://doi.org/10.1056/NEJMoa1805689
Liu J, Wang D, Ruan J, Wu G, Xu L, Jiang W, et al. Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Med. 2022;20:21. https://doi.org/10.1186/s12916-021-02219-7
Ommen Steve R, Mital S, Burke Michael A, Day Sharlene M, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76:e159-e240. https://doi.org/10.1016/j.jacc.2020.08.045
Welch TD, Ling LH, Espinosa RE, Anavekar NS, Wiste HJ, Lahr BD, et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging. 2014;7:526-534. https://doi.org/10.1161/CIRCIMAGING.113.001613
Chin CWL, Ding ZP, Lam CSP, Ling LH. Paradoxical low-gradient aortic stenosis: The HFpEF of aortic stenosis. J Am Coll Cardiol. 2016;67:2447-2448. https://doi.org/10.1016/j.jacc.2016.02.070
Dayan V, Vignolo G, Magne J, Clavel MA, Mohty D, Pibarot P. Outcome and impact of aortic valve replacement in patients with preserved LVEF and low-gradient aortic stenosis. J Am Coll Cardiol. 2015;66:2594-2603. https://doi.org/10.1016/j.jacc.2015.09.076